Farrokhi et al. showed that IL37 serum levels were higher both in patients suffering from relapsing-remitting MS (RR-MS) and those with neuromyelitis optica (NMO) as compared to healthy controls. This evidence concerns the gene IL37 and neuromyelitis optica.